Holen Sie sich die Stockscreener-App
0.2039
1.83%
0.0076
Schlusskurs vom Vortag:
$0.1963
Offen:
$0.197
24-Stunden-Volumen:
18,277
Relative Volume:
0.06
Marktkapitalisierung:
$13.43M
Einnahmen:
$598.00K
Nettoeinkommen (Verlust:
$-44.93M
KGV:
-0.0245
EPS:
-8.31
Netto-Cashflow:
$-17.32M
1W Leistung:
-7.45%
1M Leistung:
+4.66%
6M Leistung:
-80.78%
1J Leistung:
-88.31%
1-Tages-Spanne:
$0.197
$0.2066
1-Wochen-Bereich:
$0.1917
$0.23
52-Wochen-Spanne:
$0.1506
$2.625
Ernexa Therapeutics Inc Stock (ERNA) Company Profile
Firmenname
Ernexa Therapeutics Inc
Sektor
Branche
Telefon
(212) 582-1199
Adresse
1035 CAMBRIDGE STREET, CAMBRIDGE
Vergleichen Sie ERNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ERNA
Ernexa Therapeutics Inc
|
0.20 | 13.43M | 598.00K | -44.93M | -17.32M | -8.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.54 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
607.42 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
648.27 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.44 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.35 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Ernexa Therapeutics Inc Aktie (ERNA) Neueste Nachrichten
Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025 - GlobeNewswire
Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025 - The Manila Times
Ernexa Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:ERNA - Benzinga
Ernexa Therapeutics Inc Files Prospectus For Resale Of 10.4 Million Shares Of Common Stock By Selling Stockholder- SEC Filing - marketscreener.com
Eterna therapeutics sees $394,174 stock acquisition by Charles Cherington - Investing.com Australia
ERNA stock touches 52-week low at $0.16 amid sharp annual decline - Investing.com India
Ernexa Therapeutics Closes New Funding Round - GlobeNewswire
Biotech Breakthrough: Ernexa Secures $7.25M to Advance Revolutionary Cancer Treatment - Stock Titan
Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com - MarketBeat
Eterna Therapeutics announces corporate rebranding to Ernexa Therapeutics By Investing.com - Investing.com Australia
Eterna Therapeutics announces corporate rebranding to Ernexa Therapeutics - Investing.com
Eterna Therapeutics Changes Name to Ernexa Therapeutics to - GlobeNewswire
Major Pivot: Eterna Becomes Ernexa, Unveils New Cancer and Autoimmune Disease Strategy - Stock Titan
Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com - Defense World
StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - MarketBeat
Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated by Analysts at StockNews.com - Defense World
StockNews.com Begins Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - MarketBeat
Brooklyn ImmunoTherapeutics Inc (NYSE:BTX) Declares $0.09 Monthly Dividend - MarketBeat
Eterna Therapeutics sets annual meeting date, opens nominations - MSN
Better AI Stock: SoundHound AI vs. Broadcom - The Globe and Mail
Eterna Therapeutics Hosts Successful Inaugural Meeting with - GlobeNewswire
Can Eterna's Expert-Backed Cell Therapy Breakthrough Revolutionize Ovarian Cancer Treatment? - StockTitan
Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com - Defense World
Eterna Therapeutics (NASDAQ:ERNA) & Galecto (NASDAQ:GLTO) Head to Head Comparison - Defense World
Eterna Therapeutics Inc (ERNA)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by StockNews.com - Defense World
Ratio Examination: Eterna Therapeutics Inc (ERNA)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
ERNA’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Eterna Therapeutics Inc (ERNA) is a good investment, but the stock may be undervalued - US Post News
Contrasting Eterna Therapeutics (NASDAQ:ERNA) and Anixa Biosciences (NASDAQ:ANIX) - Defense World
Market Insight: Eterna Therapeutics Inc (ERNA)’s Notable Drop, Closing at 0.36 - The Dwinnex
Eterna Therapeutics expands scientific board with oncology experts - MSN
Eterna Therapeutics’ Shares Surge After Promising Preclinical Results for ERNA-101 Cell Therapy - HPBL
Finanzdaten der Ernexa Therapeutics Inc-Aktie (ERNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.01%
2.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):